TFF Pharmaceuticals Inc (TFFP) Fundamental Analysis & Valuation
NASDAQ:TFFP • US87241J2033
Current stock price
0.065 USD
-0.1 (-60.05%)
At close:
0.135 USD
+0.07 (+107.69%)
After Hours:
This TFFP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TFFP Profitability Analysis
1.1 Basic Checks
- In the past year TFFP has reported negative net income.
- In the past year TFFP has reported a negative cash flow from operations.
- TFFP had negative earnings in each of the past 5 years.
- In the past 5 years TFFP always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -261.68%, TFFP is not doing good in the industry: 92.67% of the companies in the same industry are doing better.
- TFFP's Return On Equity of -590.38% is on the low side compared to the rest of the industry. TFFP is outperformed by 81.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| ROIC | N/A |
ROA(3y)-128.2%
ROA(5y)-111.66%
ROE(3y)-147.01%
ROE(5y)-124.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TFFP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. TFFP Health Analysis
2.1 Basic Checks
- TFFP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TFFP has been reduced compared to 1 year ago.
- TFFP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- TFFP has an Altman-Z score of -34.71. This is a bad value and indicates that TFFP is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of TFFP (-34.71) is worse than 91.10% of its industry peers.
- There is no outstanding debt for TFFP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.71 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
- TFFP has a Current Ratio of 0.89. This is a bad value and indicates that TFFP is not financially healthy enough and could expect problems in meeting its short term obligations.
- TFFP's Current ratio of 0.89 is on the low side compared to the rest of the industry. TFFP is outperformed by 89.53% of its industry peers.
- A Quick Ratio of 0.89 indicates that TFFP may have some problems paying its short term obligations.
- TFFP has a worse Quick ratio (0.89) than 83.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 |
3. TFFP Growth Analysis
3.1 Past
- TFFP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.46%, which is quite impressive.
- Looking at the last year, TFFP shows a very strong growth in Revenue. The Revenue has grown by 25.57%.
EPS 1Y (TTM)50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)25.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-17.71%
3.2 Future
- TFFP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.17% yearly.
- TFFP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 153.49% yearly.
EPS Next Y65.1%
EPS Next 2Y30.1%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next Year60.13%
Revenue Next 2Y5.41%
Revenue Next 3Y153.49%
Revenue Next 5YN/A
3.3 Evolution
4. TFFP Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TFFP. In the last year negative earnings were reported.
- Also next year TFFP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TFFP's earnings are expected to grow with 21.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.1%
EPS Next 3Y21.17%
5. TFFP Dividend Analysis
5.1 Amount
- TFFP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TFFP Fundamentals: All Metrics, Ratios and Statistics
0.065
-0.1 (-60.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20 2024-11-20/amc
Earnings (Next)N/A N/A
Inst Owners22.48%
Inst Owner Change0%
Ins Owners3.36%
Ins Owner Change0%
Market Cap288.60K
Revenue(TTM)1.16M
Net Income(TTM)-18.52M
Analysts82.86
Price Target30.6 (46976.92%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.8%
Min EPS beat(2)1.96%
Max EPS beat(2)29.64%
EPS beat(4)3
Avg EPS beat(4)8.63%
Min EPS beat(4)-4.11%
Max EPS beat(4)29.64%
EPS beat(8)7
Avg EPS beat(8)20.47%
EPS beat(12)9
Avg EPS beat(12)12.21%
EPS beat(16)10
Avg EPS beat(16)4.34%
Revenue beat(2)1
Avg Revenue beat(2)159.82%
Min Revenue beat(2)-5.2%
Max Revenue beat(2)324.84%
Revenue beat(4)3
Avg Revenue beat(4)124.27%
Min Revenue beat(4)-5.2%
Max Revenue beat(4)324.84%
Revenue beat(8)6
Avg Revenue beat(8)325.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)22.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)166.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.09 | ||
| P/tB | 0.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.44
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0.26
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-128.2%
ROA(5y)-111.66%
ROE(3y)-147.01%
ROE(5y)-124.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | -34.71 |
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)402.4%
Cap/Depr(5y)N/A
Cap/Sales(3y)429.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y65.1%
EPS Next 2Y30.1%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue 1Y (TTM)25.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-17.71%
Revenue Next Year60.13%
Revenue Next 2Y5.41%
Revenue Next 3Y153.49%
Revenue Next 5YN/A
EBIT growth 1Y21.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year209.69%
EBIT Next 3Y45.36%
EBIT Next 5YN/A
FCF growth 1Y60.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.76%
OCF growth 3YN/A
OCF growth 5YN/A
TFF Pharmaceuticals Inc / TFFP Fundamental Analysis FAQ
What is the fundamental rating for TFFP stock?
ChartMill assigns a fundamental rating of 3 / 10 to TFFP.
Can you provide the valuation status for TFF Pharmaceuticals Inc?
ChartMill assigns a valuation rating of 1 / 10 to TFF Pharmaceuticals Inc (TFFP). This can be considered as Overvalued.
How profitable is TFF Pharmaceuticals Inc (TFFP) stock?
TFF Pharmaceuticals Inc (TFFP) has a profitability rating of 0 / 10.
What is the expected EPS growth for TFF Pharmaceuticals Inc (TFFP) stock?
The Earnings per Share (EPS) of TFF Pharmaceuticals Inc (TFFP) is expected to grow by 65.1% in the next year.